Cargando…
Fludrocortisone Is Associated With a Higher Risk of All‐Cause Hospitalizations Compared With Midodrine in Patients With Orthostatic Hypotension
BACKGROUND: Orthostatic hypotension causes ≈80 000 hospitalizations per year in the United States. Treatments for orthostatic hypotension include fludrocortisone, a mineralocorticoid analog that promotes sodium reabsorption; and midodrine, an α‐1 adrenergic agonist that is a direct vasoconstrictor....
Autores principales: | Grijalva, Carlos G., Biaggioni, Italo, Griffin, Marie R., Shibao, Cyndya A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721876/ https://www.ncbi.nlm.nih.gov/pubmed/29025750 http://dx.doi.org/10.1161/JAHA.117.006848 |
Ejemplares similares
-
Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease
por: Kremens, Daniel, et al.
Publicado: (2017) -
Midodrine for orthostatic hypotension
Publicado: (2020) -
Long-Term Outcomes of Hyperadrenergic Orthostatic Hypotension
por: Castro, Robert Alexander, et al.
Publicado: (2023) -
2198 Cognitive and behavioral side effects in patients treated with droxidopa for neurogenic orthostatic hypotension
por: McDonell, Katherine, et al.
Publicado: (2018) -
Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial
por: Kaufmann, Horacio, et al.
Publicado: (2021)